



ASX ANNOUNCEMENT

30 September 2026

Vitrafy enters partnership with Versiti Blood Health

Vitrafy Life Sciences Ltd ("**Vitrafy**" or "**the Company**") (ASX: **VFY**) has entered into a partnership with Versiti Blood Health, Inc. ("**Versiti**"), a U.S. non-profit blood network, to advance development of Vitrafy's cryopreservation ecosystem for platelets. The partnership follows the Company's in-vitro platelet study with the United States Army Institute of Surgical Research ("**USAISR**") and will also support verification and validation activities associated with Vitrafy's planned U.S. medical device listing.

The partnership follows the Phase II in-vitro platelet study conducted by the USAISR (announced 22 May 2026), in which the 3% DMSO no-wash protocol achieved 94.4% mean post-thaw platelet recovery using Vitrafy's cryopreservation ecosystem. Use of the Vitrafy ecosystem for cryopreserved platelets remains in development and is subject to U.S. regulatory requirements.

Versiti is Vitrafy's third U.S. civilian blood partnership, following the previously announced partnerships with Vitalant and Hoxworth Blood Center, both of which are focused on red blood cells. The Versiti partnership is focused on platelets.

Under the partnership, Vitrafy and Versiti will each contribute resources to advance development of Vitrafy's cryopreservation ecosystem for no-wash platelet cryopreservation within Versiti's platelet workflows.

Separately, blood products supplied under the partnership will support verification and validation activities for Vitrafy's cryopreservation freezer for currently approved cryopreserved blood products, such as plasma. These activities are directed at completing U.S. medical device listing for Vitrafy's cryopreservation freezer, targeted for FY2027.

Versiti also intends to explore the application of the Vitrafy cryopreservation ecosystem to other blood products, including red blood cells.

Vitrafy will initially place two cryopreservation freezing units at Versiti's Blood Research Institute facility in Milwaukee, Wisconsin. The units will be provided without charge and the placement will not generate revenue. Vitrafy will fund certain verification and validation services undertaken by Versiti on the Company's behalf related to the FDA medical device listing process currently underway.

About Versiti

Versiti Blood Health, Inc. is a non-profit blood health organisation operating 42 fixed collection centres and serving more than 400 hospitals across the Midwest.

Versiti collects, tests and distributes blood and blood products to hospitals across five Midwest states (Illinois, Indiana, Michigan, Ohio and Wisconsin) through a network of fixed donor centres and mobile blood drives.

Versiti also operates the Versiti Blood Research Institute, which conducts research in hematology, transfusion medicine and cellular therapy, and operates diagnostic laboratories.



Outlook

Upon finalisation of the partnership Managing Director and CEO, **Brent Owens**, commented:

The Versiti partnership is the third major civilian blood network to come to us directly off the back of the USAISR platelets studies, and the first focused specifically on platelets. Vitrafy's aim is to help supply hospitals with high-quality cryopreserved platelets — overcoming the seven-day shelf life that constrains today's supply and easing the platelet shortages that 33% of hospitals¹ report facing in life-saving scenarios every day."

- ENDS -

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Adrian Mulcahy
Automic Markets
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardion cryopreservation freezing unit and LifeChain™, a cloud-based software platform. The ecosystem is designed to support the collection, cryopreservation, storage and delivery of sensitive biological materials.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit [vitrafy.com](https://www.vitrafy.com).

¹ <https://www.washingtonpost.com/wellness/2023/10/15/blood-transfusion-shortage-crisis/>